ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024
ANI Pharmaceuticals (ANIP) announced its upcoming presentation of new pre-clinical data on membranous nephropathy (MN) research at the American Society of Nephrology Kidney Week 2024 in San Diego, October 23-27. The company will showcase two poster presentations focusing on THSD7A-associated membranous nephropathy and melanocortin therapy's protective effects.
Chief Medical Officer Dr. Mary Pao highlighted the significance of their research in understanding melanocortin receptors' role in nephrotic syndrome. The presentations will be delivered by lead author Jing Liu, with sessions scheduled for October 25 and 26.
ANI Pharmaceuticals (ANIP) ha annunciato la sua prossima presentazione di nuovi dati pre-clinici sulla ricerca relativa alla nefrite membranosa (MN) durante la American Society of Nephrology Kidney Week 2024 a San Diego, dal 23 al 27 ottobre. L'azienda presenterà due poster che si concentrano sulla nefrite membranosa associata a THSD7A e sugli effetti protettivi della terapia con melanocortina.
La Direttore Medico Dr. Mary Pao ha sottolineato l'importanza della loro ricerca nella comprensione del ruolo dei recettori della melanocortina nella sindrome nefrotica. Le presentazioni saranno tenute dall'autore principale Jing Liu, con sessioni programmate per il 25 e 26 ottobre.
ANI Pharmaceuticals (ANIP) anunció su próxima presentación de nuevos datos preclínicos sobre la investigación de nefropatía membranosa (MN) en la Semana del Riñón de la Sociedad Americana de Nefrología 2024 en San Diego, del 23 al 27 de octubre. La compañía exhibirá dos presentaciones en póster centradas en la nefropatía membranosa asociada a THSD7A y los efectos protectores de la terapia de melanocortina.
La Directora Médica Dra. Mary Pao destacó la importancia de su investigación para comprender el papel de los receptores de melanocortina en el síndrome nefrótico. Las presentaciones serán realizadas por el autor principal Jing Liu, con sesiones programadas para el 25 y 26 de octubre.
ANI Pharmaceuticals (ANIP)는 막신우신염(MN) 연구에 대한 새로운 전임상 데이터 발표를 오는 2024년 미국 신장학회에서 샌디에이고에서 10월 23일부터 27일까지 진행한다고 발표했습니다. 이 회사는 THSD7A와 관련된 막신우신염 및 멜라노코르틴 치료의 보호 효과에 중점을 둔 두 가지 포스터 발표를 선보일 예정입니다.
의학부 장관인 메리 파오 박사는 신증후군에서 멜라노코르틴 수용체의 역할을 이해하는 연구의 중요성을 강조했습니다. 발표는 주요 저자인 징 리우가 진행하며, 세션은 10월 25일과 26일로 예정되어 있습니다.
ANI Pharmaceuticals (ANIP) a annoncé sa prochaine présentation de nouvelles données précliniques sur la recherche concernant la néphropathie membranosa (MN) lors de la Semaine des reins de la Société Américaine de Néphrologie 2024 à San Diego, du 23 au 27 octobre. L'entreprise présentera deux affiches axées sur la néphropathie membranosa associée à THSD7A et les effets protecteurs de la thérapie par les mélanocortines.
La directrice médicale Dr. Mary Pao a souligné l'importance de leur recherche pour comprendre le rôle des récepteurs de mélanocortine dans le syndrome néphrotique. Les présentations seront effectuées par l'auteur principal Jing Liu, avec des sessions prévues pour les 25 et 26 octobre.
ANI Pharmaceuticals (ANIP) hat die bevorstehende Präsentation neuer präklinischer Daten zur Forschung über membranöse Nephropathie (MN) während der American Society of Nephrology Kidney Week 2024 in San Diego, vom 23. bis 27. Oktober, angekündigt. Das Unternehmen wird zwei Posterpräsentationen präsentieren, die sich auf die THSD7A-assoziierte membranöse Nephropathie und die schützenden Effekte der Melanocortintherapie konzentrieren.
Die Chief Medical Officer Dr. Mary Pao betonte die Bedeutung ihrer Forschung zum Verständnis der Rolle der Melanocortin-Rezeptoren im nephrotischen Syndrom. Die Präsentationen werden vom Hauptautoren Jing Liu durchgeführt, mit Sitzungen, die für den 25. und 26. Oktober geplant sind.
- None.
- None.
Two poster presentations demonstrate ANI’s commitment to research in membranous nephropathy care
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its membranous nephropathy (MN) research during two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27.
"We are excited to share our data with the ASN 2024 community. These data shed light of the potential role of melanocortin receptors in the underlying disease pathologies within nephrotic syndrome,” said Mary Pao, MD, PhD, Chief Medical Officer of ANI “This research contributes to the development of valuable research tools and models for studying membranous nephropathy. The findings represent the first steps in ANI’s commitment to advancing the science underlying certain disease pathologies.”
Poster Title: THSD7A-Associated Membranous Nephropathy Involves Both Complement-Mediated and Autonomous Podocyte Injury
Poster Session: Pathology and Lab Medicine - 1
Abstract: FR-PO955
Presentation Time: Friday, Oct. 25, 10:00 AM-12:00 PM
Lead Author: Jing Liu
Poster Title: Activation of Podocyte-Specific MC5R Signaling by Melanocortin Therapy Protects Against THSD7A-Associated Membranous Nephropathy
Poster Session: Glomerular Diseases: Therapeutic Strategies
Abstract: SA-PO715
Presentation Time: Saturday, Oct. 26, 10:00 AM-12:00 PM
Lead Author: Jing Liu
The abstracts are available online at asn-online.org. For more information during the conference, visit the ANI Pharmaceuticals booth.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. ANI is focused on delivering sustainable growth by scaling up its Rare Disease business, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, visit www.anipharmaceuticals.com.
Forward-Looking Statements
This press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “continue,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “shall,” “would” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the ability to implement business plans, forecasts, and other expectations in connection with the acquisition and integration of Alimera Sciences, Inc. (“Alimera”) and identify and realize additional opportunities and, in particular, the possibility that the Company is unable to achieve anticipated synergies, (ii) costs and regulatory requirements relating to contract manufacturing arrangements, (iii) costs or delays associated with manufacturing (including the sources and any changes in sources thereof) of the Company’s products, (iv) delays or failures in retaining and obtaining continuing and future product approvals from the FDA, and other regulatory issues relating to the Company's business and products, (v) market trends for the Company’s products, and the ability to achieve anticipated sales for such products, (vi) risks that the acquisition of Alimera may disrupt current plans and operations of the Company and potential difficulties of the Company in retaining employees of Alimera and/or maintaining business relationships of Alimera, (vii) the impact of any litigation to which the Company is, or may become, a party, including in connection with the acquisition and integration thereof, (viii) volatility in the Company’s stock price, including as a result of the acquisition, (ix) changes in competitive and regulated industries in which the Company operates, variations in operating performance across competitors, changes in laws and regulations affecting the Company’s business, and changes in the Company’s capital structure as a result of the acquisition, (x) regulatory and other approvals relating to product development and manufacturing, (xi) the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries and/or the Company and its products, (xii) costs incurred in connection with the acquisition of Alimera and the possibility that the Company is unable to realize anticipated benefits of the acquisition or to realize estimated pro forma results and underlying assumptions, (xiii) delays in production, increased costs and potential loss of revenues if there is a change in manufacturers or manufacturing processes due to the limited number of suppliers for the Company’s raw materials, active pharmaceutical ingredients, excipients and other materials, (xiv) the Company’s reliance on single source third-party contract manufacturing supply for certain of its key products, (xv) changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration, and other regulatory agencies, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions, (xvi) the impact of legislative or regulatory reform on the pricing for the Company’s products, (xvii) the Company’ ability to maintain the services of its key executives and other personnel, and (xviii) general business and economic conditions, such as inflationary pressures, geopolitical conditions including, but not limited to, the conflict between Russia and the Ukraine, the conflict between Israel and Gaza, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies. More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Media Contact:
Chris Saunders
T: 484-794-6525
E: chris.saunders@anipharmaceuticals.com
Source: ANI Pharmaceuticals, Inc.
FAQ
What research will ANI Pharmaceuticals (ANIP) present at ASN Kidney Week 2024?
When and where is ANI Pharmaceuticals (ANIP) presenting at ASN Kidney Week 2024?
What are the main topics of ANI Pharmaceuticals' (ANIP) poster presentations at ASN 2024?
